ANDA 204920, held by PharmoBedient. Esomeprazole Magnesium; Naproxen.
As of Nov 21, 2026, ANDA 204920 (Naproxen and Esomeprazole Magnesium), held by PharmoBedient, was first approved by FDA on Jul 20, 2021, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 20, 2021 | Original application | Approved | None posted |
| Naproxen and Esomeprazole MagnesiumEQ 20MG BASE;375MG · tablet, delayed release;oral | Esomeprazole Magnesium; Naproxen | Discontinued |
| Naproxen and Esomeprazole MagnesiumEQ 20MG BASE;500MG · tablet, delayed release;oral | Esomeprazole Magnesium; Naproxen | Discontinued |
| Apr 2, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 21, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 15, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 15, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 20, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters